17 steady state er eksponering 66% højere hos patienter med beskeden metabolisme i forhold til patienter med stor metabolisme.
However, a population pharmacokinetic analyses of Phase III data indicated that on average steady-state exposure is 66% higher in poor metabolisers than in extensive metabolisers.